Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season Read More »
